Last reviewed · How we verify
BNC 105
At a glance
| Generic name | BNC 105 |
|---|---|
| Sponsor | Australasian Gastro-Intestinal Trials Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of BNC105P Combined With Ibrutinib (PHASE1)
- Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNC 105 CI brief — competitive landscape report
- BNC 105 updates RSS · CI watch RSS
- Australasian Gastro-Intestinal Trials Group portfolio CI